A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials

DOI10.1111/J.1541-0420.2011.01608.XMaRDI QIDQ2893404zbMATH OpenOpenAlexWikidataFDO

Authors Yun Li, Roderick Little, Jeremy M. G. Taylor

Publication date 20 June 2012

Published in Biometrics (Search for Journal in Brave)

Full work available at URL http://europepmc.org/articles/pmc3365575

zbMATH Keywords

missing dataridge regressionauxiliary variablebiomarkerrandomized trials

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Model-free approach to quantifying the proportion of treatment effect explained by a surrogate marker
• Evaluation of longitudinal surrogate markers
• A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
• A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
• On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm

Cites work

• A Generalization of Sampling Without Replacement From a Finite Universe
• A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
• Adjusting for Nonignorable Drop-Out Using Semiparametric Nonresponse Models
• Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
• Nonparametric Survival Estimation Using Prognostic Longitudinal Covariates
• Properties of A Nonparametric Test for Early Comparison of Treatments in Clinical Trials in the Presence of Surrogate Endpoints
• Some comments on efficiency gains from auxiliary information for right-censored data
• Survival analysis using auxiliary variables via multiple imputation, with application to AIDS clinical trial data
• The validation of surrogate endpoints in meta-analyses of randomized experiments

Cited in

(3)

• Landmark estimation of survival and treatment effects in observational studies
• Improving efficiency in clinical trials using auxiliary information: Application of a multi‐state cure model
• Bias reduction using surrogate endpoints as auxiliary variables

This page was built for publication: A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2893404)